PP46 Budget Impact Analysis Of Tafenoquine Following The G6PD Test For Treatment Of Plasmodium Vivax Malaria In The Brazilian Amazon
Marcia Pinto, Ivan Zimmermann, Márcia Gisele Costa, Ana Carolina Carioca da Costa · 2025
Read PP46 Budget Impact Analysis Of Tafenoquine Following The G6PD Test For Treatment Of Plasmodium Vivax Malaria In The Brazilian Amazon by Marcia Pinto, Ivan Zimmermann, Márcia Gisele Costa, Ana Carolina Carioca da Costa (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12768794.txt.
Description
Marcia Pinto and three co-authors wrote a 2025 study on the budget cost of a new malaria treatment plan in the Brazilian Amazon. Nearly all malaria in Brazil occurs in that region, and most of it is the vivax type. A single-dose drug, tafenoquine, can clear that type, but it can badly harm people who lack a certain enzyme.
So the plan pairs the drug with a test for that enzyme lack, called G6PD deficiency. The team modeled the added cost to the public system over five years. They compared current care with the new plan, at full rollout. The added cost came to about 6.26 million dollars over the five years. Policy makers reviewed the model in joint meetings. The study helps Brazil weigh the price of a simpler cure.
Catalog record
| CREATOR | Marcia Pinto, Ivan Zimmermann, Márcia Gisele Costa, Ana Carolina Carioca da Costa |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 2 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |